Dysplastic Nevi

New England Journal of Medicine

Volumn 349, Issue 23, 2003, Pages 2233-2240

  Naeyaert, Jean Marie ^a   Brochez, Lieve ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; DYSPLASTIC NEVUS; FAMILY HISTORY; HUMAN; MALE; MEDICAL EXAMINATION; PRIORITY JOURNAL; MELANOMA; MICROSCOPY; PATHOLOGY; PRACTICE GUIDELINE; REVIEW; SKIN TUMOR;

SUNSCREEN;

ADULT; DYSPLASTIC NEVUS SYNDROME; HUMANS; MALE; MELANOMA; MICROSCOPY; PRACTICE GUIDELINES; SKIN NEOPLASMS; SUNSCREENING AGENTS;

EID: 0345305783     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMcp023017     Document Type: Article

References (59)

1. Clark WH, Reimer RR, Greene MH, Ainsworth AM, Mastrangelo MJ. Origin of familial malignant melanomas from heritable melanocytic lesons: 'the B-K mole syndrome.' Arch Dermatol 1978;114:732-8.
2. Tsao H, Sober AJ. Atypical melanocytic nevi. In: Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, eds. Fitzpatrick's dermatology in general medicine. 6th ed. New York: McGraw-Hill, 2003:906-16.
3. Richard MA, Grob JJ, Gouvernet J, et al. Role of sun exposure on nevus: first study in age-sex phenotype-controlled populations. Arch Dermatol 1993;129:1280-5.
4. Tucker MA, Greene MH, Clark WH Jr, Kraemer KH, Fraser MC, Elder DE. Dysplastic nevi on the scalp of prepubertal children from melanoma-prone families. J Pediatr 1983;103:65-9.
5. Halpern AC, Guerry DIV, Elder DE, Trock B, Synnestvedt M, Humphreys T. Natural history of dysplastic nevi. J Am Acad Dermatol 1993;29:51-7.
6. Elder DE, Goldman LI, Goldman SC, Greene MH, Clark WH Jr. Dysplastic nevus syndrome: a phenotypic association of sporadic cutaneous melanoma. Cancer 1980;46:1787-94.
7. Kopf AW, Friedman RJ, Rigel DS, Atypical mole syndrome. J Am Acad Dermatol 1990;22:117-8.
8. Crijns MB, Vink J, Van Hees CLM, Bergman W, Vermeer BJ. Dysplastic nevi: occurrence in first- and second-degree relatives of patients with 'sporadic' dysplastic nevus syndrome. Arch Dermatol 1991;127:1346-51.
9. Crijns MB, Vink J, Van Hees CLM, Bergman W, Vermeer BJ. Dysplastic nevi: occurrence in first- and second-degree relatives of patients with 'sporadic' dysplastic nevus syndrome. Arch Dermatol 1991;127:1346-51.
10. Bishop JA, Bradburn M, Bergman W, et al. Teaching non-specialist health care professionals how to identify the atypical mole syndrome phenotype: a multinational study. Br J Dermatol 2000;142:331-7.
11. Clemente C, Cochran AJ, Elder DE, et al. Histopathologic diagnosis of dysplastic nevi: concordance among pathologists convened by the World Health Organisation Melanoma Programme. Hum Pathol 1991;22:313-9.
12. de Wit PEJ, van't Hof-Grootenboer B, Ruiter DJ, et al. Validity of the histopathological criteria used for diagnosing dysplastic naevi: an interobserver study by the pathology subgroup of the EORTC Malignant Melanoma Cooperative Group. Eur J Cancer 1993;29A:831-9.
13. Duncan LM, Berwick M, Bruijn JA, Byers HR, Mihm MC, Barnhill RL. Histopathologic recognition and grading of dysplastic melanocytic nevi: an interobserver agreement study. J Invest Dermatol 1993;100:318S-321S.
14. Duray PH, DerSimonian R, Barnhill R, et al. An analysis of interobserver recognition of the histopathologic features of dysplastic nevi from a mixed group of nevomelanocytic lesions. J Am Acad Dermatol 1992;27:741-9.
15. Grob JJ, Andrac L, Romano MH, et al. Dysplastic naevus in non-familial melanoma: a clinicopathological study of 101 cases. Br J Dermatol 1988;118:745-52.
16. Klein LJ, Barr RJ. Histologic atypia in clinically benign nevi: a prospective study. J Am Acad Dermatol 1990;22:275-82.
17. Piepkorn M, Meyer LJ, Goldgar D, et al. The dysplastic melanocytic nevus: a prevalent lesion that correlates poorly with clinical phenotype. J Am Acad Dermatol 1989;20:407-15.
18. Halpern AC, Guerry D IV, Elder DE, et al. Dysplastic nevi as risk markers of sporadic (nonfamilial) melanoma: a case-control study. Arch Dermatol 1991;127:995-9.
19. Augustsson A, Stierner U, Rosdahl I, Suurküla M. Common and dysplastic naevi as risk factors for cutaneous malignant melanoma in a Swedish population. Acta Derm Venereol 1991;71:518-24.
20. Piepkorn MW, Barnhill RL, Cannon-Albright LA, et al. A multiobserver, population-based analysis of histologic dysplasia in melanocytic nevi. J Am Acad Dermatol 1994;30:707-14.
21. Steijlen PM, Bergman W, Hermans J, Scheffer E, Van Vloten WA, Kuiter DJ. The efficacy of histopathological criteria required for diagnosing dysplastic naevi. Histopathology 1988;12:289-300.
22. Holly EA, Kelly JW, Shpall SN, Chiu SH. Number of melanocytic nevi as a major risk factor for malignant melanoma. J Am Acad Dermatol 1987;17:459-68.
23. Grob JJ, Gouvernet J, Aymar D, et al. Count of benign melanocytic nevi as a major indicator of risk for nonfamilial nodular and superficial spreading melanoma. Cancer 1990;66:387-95.
24. Garbe C, Büttner P, Weiss J, et al. Risk factors for developing cutaneous melanoma and criteria for identifying persons at risk: multicenter case-control study of the Central Malignant Melanoma Registry of the German Dermatological Society. J Invest Dermatol 1994;102:695-9.
25. Tucker MA, Halpern A, Holly EA, et al. Clinically recognized dysplastic nevi: a central risk factor for cutaneous melanoma. JAMA 1997;277:1439-44.
26. Bataille V, Grulich A, Sasieni P, et al. The association between naevi and melanoma in populations with different levels of sun exposure: a joint case-control study of melanoma in the UK and Australia. Br J Cancer 1998;77:505-10.
27. Clark WH Jr, Elder DE, Guerry DIV, Epstein MN, Greene MH, Van Horn M. A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Hum Pathol 1984;15:1147-65.
28. Tucker MA, Fraser MC, Goldstein AM, Elder DE, Guerry D IV, Organic SM. The risk of melanoma and other cancers in melanoma-prone families. J Invest Dermatol 1993;100:350S-355S.
29. Carey WP Jr, Thompson CJ, Synnestvedt M, et al. Dysplastic nevi as a melanoma risk factor in patients with familial melanoma. Cancer 1994;74:3118-25.
30. Rigel DS, Rivers JK, Kopf AW, et al. Dysplastic nevi: markers of increased risk for melanoma. Cancer 1989;63:386-9.
31. Tiersten AD, Grin CM, Kopf AW, et al. Prospective follow-up for malignant melanoma in patients with atypical-mole (dysplastic-nevus) syndrome. J Dermatol Surg Oncol 1991;17:44-8.
32. Halpern AC, Guerry D IV, Elder DE, Trock B, Synnestvedt M. A cohort study of melanoma in patients with dysplastic nevi. J Invest Dermatol 1993;100:346S-349S.
33. MacKie PM, McHenry P, Hole D. Accelerated detection with prospective surveillance for cutaneous malignant melanoma in high-risk groups. Lancet 1993;341:1618-20.
34. Kang S, Barnhill RL, Mihm MC Jr, Fitzpatrick TB, Sober AJ. Melanoma risk in individuals with clinically atypical nevi. Arch Dermatol 1994;130:999-1001.
35. Marghoob AA, Kopf AW, Rigel DS, et al. Risk of cutaneous malignant melanoma in patients with 'classic' atypical-mole syndrome: a case-control study. Arch Dermatol 1994;130:993-8.
36. Swerdlow AJ, English J, MacKie RM, et al. Benign melanocytic naevi as a risk factor for malignant melanoma. Br Med J (Clin Res Ed) 1986;292:1555-9.
37. Burden AD, Newell J, Andrew N, Kavanagh G, Connor JM, MacKie RM. Genetic and environmental influences in the development of multiple primary melanoma. Arch Dermatol 1999;135:261-5.
38. Masri GD, Clark WH Jr, Guerry D IV, Halpern A, Thompson CJ, Elder DE. Screening and surveillance of patients at high risk for malignant melanoma result in detection of earlier disease. J Am Acad Dermatol 1990;22:1042-8.
39. Sagebiel RW. Melanocytic nevi in histological association with primary cutaneous melanoma of superficial spreading and nodular types: effect of tumour thickness. J Invest Dermatol 1993;100:322S-325S.
40. Rhodes AR, Harrist TJ, Day CL, Mihm MC Jr, Fitzpatrick TB, Sober AJ. Dysplastic melanocytic nevi in histologic association with 234 primary cutaneous melanomas. J Am Acad Dermatol 1983;9:563-74.
41. Brochez J, Verhaeghe E, Grosshans E, et al. Inter-observer variation in the histopathological diagnosis of clinically suspicious pigmented skin lesions. J Pathol 2002;196:459-66.
42. Rhodes AR. Intervention strategy to prevent lethal cutaneous melanoma: use of dermatologic photography to aid surveillance of high-risk persons. J Am Acad Dermatol 1998;39:262-7.
43. Berwick M, Begg CB, Fine JA, Roush GC, Barnhill RL. Screening for cutaneous melanoma by skin self-examination. J Natl Cancer Inst 1996;88:17-23.
44. Carli P, De Giorgi V, Palli D, et al. Dermatologist detection and skin self-examination are associated with thinner melanomas: results from a survey of the Italian Multidisciplinary Group on Melanoma. Arch Dermatol 2003;139:607-12.
45. Bataille V, Sasieni P, Cuzick J, Hungerford JL, Swerdlow A, Bishop JA. Risk of ocular melanoma in relation to cutaneous and iris naevi. Int J Cancer 1995;60:622-6.
46. Vink J, Crijns MB, Mooy CM, Bergman W, Oosterhuis JA, Went LN. Ocular melanoma in families with dysplastic nevus syndrome. J Am Acad Dermatol 1990;23:858-62.
47. Taylor MR, Guerry D IV, Bondi EE, et al. Lack of association between intraocular melanoma and cutaneous dysplastic nevi. Am J Ophthalmol 1984;98:478-82.
48. Kefford RF, Newton Bishop JA, Bergman W, Tucker MA. Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: a consensus statement of the Melanoma Genetics Consortium. J Clin Oncol 1999;17:3245-51.
49. Bishop JA, Wachsmuth RC, Harland M, et al. Genotype/phenotype and penetrance studies in melanoma families with germline CDKN2A mutations. J Invest Dermatol 2000;114:28-33.
50. Autier P, Doré JF, Cattaruzza MS, et al. Sunscreen use, wearing clothes, and number of nevi in 6- to 7-year-old European children. J Natl Cancer Inst 1998;90:1873-80.
51. Gallagher RP, Rivers JK, Lee TK, Bajdik CD, McLean DI, Coldman AJ. Broad-spectrum sunscreen use and the development of new nevi in white children: a randomized controlled trial. JAMA 2000;283:2955-60.
52. Autier P. Sunscreen and melanoma revisited. Arch Dermatol 2000;136:423.
53. Stolz W, Semmelmayer U, Johow K, Burgdorf WH. Principles of dermatoscopy of pigmented skin lesions. Semin Cutan Med Surg 2003;22:9-20.
54. Pehamberger H, Binder M, Steiner A, WolffK. In vivo epiluminescence microscopy: improvement of early diagnosis of melanoma. J Invest Dermatol 1993;100:356S-362S.
55. Menzies SW, Ingvar C, Crotty KA, McCarthy WH. Frequency and morphologic characteristics of invasive melanomas lacking specific surface microscopic features. Arch Dermatol 1996;132:1178-82.
56. Argenziano G, Fabbrocini G, Carli P, De Giorgi V, Sammarco E, Delfino M. Epiluminescence microscopy for the diagnosis of doubtful melanocytic skin lesions: comparison of the ABCD rule of dermatoscopy and a new 7-point checklist based on pattern analysis. Arch Dermatol 1998;134:1563-70.
57. Dal Pozzo V, Benelli C, Roscetti E. The seven features for melanoma: a new dermoscopic algorithm for the diagnosis of malignant melanoma. Eur J Dermatol 1999;9:303-8.
58. Bergman W, Van Voorst Vader PC, Ruiter DJ. Dysplastic naevi and the risk of melanoma: a guideline for patient care. Ned Tijdschr Geneeskd 1997;141:2010-4.
59. NIH Consensus Conference: diagnosis and treatment of early melanoma. JAMA 1992;268:1314-9.